203 related articles for article (PubMed ID: 17852022)
21. The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS).
Vardeny O; Bromberg MB
J Herb Pharmacother; 2005; 5(3):23-31. PubMed ID: 16520295
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
van Kan HJ; van den Berg LH; Groeneveld GJ; van der Straaten RJ; van Vught PW; Lie-A-Huen L; Guchelaar HJ
Biopharm Drug Dispos; 2008 Apr; 29(3):139-44. PubMed ID: 18098330
[TBL] [Abstract][Full Text] [Related]
23. [Tolerance of riluzole in a phase IIIb clinical trial].
Lacomblez L; Dib M; Doppler V; Faudet A; Robin V; Salachas F; Bensimon G; Meininger V
Therapie; 2002; 57(1):65-71. PubMed ID: 12090150
[TBL] [Abstract][Full Text] [Related]
24. Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.
Söderberg MM; Haslemo T; Molden E; Dahl ML
Pharmacogenet Genomics; 2013 May; 23(5):279-85. PubMed ID: 23492908
[TBL] [Abstract][Full Text] [Related]
25. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.
Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE
Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927
[TBL] [Abstract][Full Text] [Related]
26. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
[TBL] [Abstract][Full Text] [Related]
27. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population.
B'chir F; Pavanello S; Knani J; Boughattas S; Arnaud MJ; Saguem S
Life Sci; 2009 May; 84(21-22):779-84. PubMed ID: 19332078
[TBL] [Abstract][Full Text] [Related]
28. A novel gender-related difference in the constitutive expression of hepatic cytochrome P4501A subfamily enzymes in Meishan pigs.
Kojima M; Sekimoto M; Degawa M
Biochem Pharmacol; 2008 Mar; 75(5):1076-82. PubMed ID: 18068149
[TBL] [Abstract][Full Text] [Related]
29. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements.
Yoshinari K; Ueda R; Kusano K; Yoshimura T; Nagata K; Yamazoe Y
Biochem Pharmacol; 2008 Jul; 76(1):139-45. PubMed ID: 18502397
[TBL] [Abstract][Full Text] [Related]
30. [Riluzole as a treatment for amyotrophic lateral sclerosis].
Borrás-Blasco J; Plaza-Macías I; Navarro-Ruiz A; Perís-Martí J; Antón-Cano A
Rev Neurol; 1998 Dec; 27(160):1021-7. PubMed ID: 9951030
[TBL] [Abstract][Full Text] [Related]
31. Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides.
Tsatsakis AM; Zafiropoulos A; Tzatzarakis MN; Tzanakakis GN; Kafatos A
Toxicol Lett; 2009 Apr; 186(1):66-72. PubMed ID: 19022366
[TBL] [Abstract][Full Text] [Related]
32. CYP1A1 polymorphisms and the risk of upper aerodigestive tract cancers in an Indian population.
Sam SS; Thomas V; Reddy SK; Surianarayanan G; Chandrasekaran A
Head Neck; 2008 Dec; 30(12):1566-74. PubMed ID: 18767181
[TBL] [Abstract][Full Text] [Related]
33. Biochemical alterations associated with ALS.
Lawton KA; Cudkowicz ME; Brown MV; Alexander D; Caffrey R; Wulff JE; Bowser R; Lawson R; Jaffa M; Milburn MV; Ryals JA; Berry JD
Amyotroph Lateral Scler; 2012 Jan; 13(1):110-8. PubMed ID: 22117131
[TBL] [Abstract][Full Text] [Related]
34. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis.
Stefan K; Kunesch E; Benecke R; Classen J
Ann Neurol; 2001 Apr; 49(4):536-9. PubMed ID: 11310635
[TBL] [Abstract][Full Text] [Related]
35. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia.
Tay JK; Tan CH; Chong SA; Tan EC
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1297-302. PubMed ID: 17611010
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms of cytochrome P450 1A1, cigarette smoking and risk of coronary artery disease.
Yeh CC; Sung FC; Kuo LT; Hsu WP; Chu HY
Mutat Res; 2009 Jul; 667(1-2):77-81. PubMed ID: 19563927
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India.
Srivastava DS; Mandhani A; Mittal RD
Arch Toxicol; 2008 Sep; 82(9):633-9. PubMed ID: 18200441
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
Li M; Guan TY; Li Y; Na YQ
Chin Med J (Engl); 2008 Feb; 121(4):305-8. PubMed ID: 18304461
[TBL] [Abstract][Full Text] [Related]
39. Slowing down ALS--is this good or bad?
Munsat TL
Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2 Suppl 1():S19-22. PubMed ID: 11465919
[TBL] [Abstract][Full Text] [Related]
40. What are the implications of early diagnosis? Maintaining optimal health as long as possible.
Brooks BR
Neurology; 1999; 53(8 Suppl 5):S43-5; discussion S55-7. PubMed ID: 10560637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
